VERNON HILLS, Ill., Feb. 2 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that the Company will hold a conference call on Thursday, February 9, 2006 at 4:30 P.M. EST. The call will last for up to one hour. Management will present an update on Company progress and results of operations. Additional materials related to the presentation will be disseminated by press release and on the Company's website before the call. Investors and interested parties will have the opportunity to join the call by dialing (877) 497-0736 and registering with the operator. To insure that you will have access to the call, please call and register with the operator no later than 10 minutes prior to the start of the call.
About Immtech
Immtech International, Inc. is a pharmaceutical company focused on commercializing drugs to treat infectious diseases and aims to expand its markets by targeting other disorders. It has advanced clinical programs that include new treatments for malaria, Pneumocystis pneumonia and African sleeping sickness (trypanosomiasis). Immtech has worldwide licensing and exclusive commercialization rights to a large library of well-defined pharmaceutical compounds, and the Company is broadening the application of its intellectual property portfolio. For additional information, please go to http://www.immtech-international.com/.
"Safe Harbor" Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report on Form 10-K for the most recently ended fiscal year.
First Call Analyst:
FCMN Contact: kara@rlcinc.com
